PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Bremelanotide — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Bremelanotide is a synthetic peptide analogue of alpha-melanocyte-stimulating hormone with high affinity for the melanocortin-4 receptor. · pmid:31429064

History

It was approved in the USA in 2019 as an on-demand subcutaneous therapy for premenopausal women with acquired, generalized hypoactive sexual desire disorder. · pmid:31429064

In two phase 3 trials randomizing 1,267 women, it increased desire scores and reduced related distress compared with placebo, with more nausea, flushing and headache. · pmid:31599840

Identity

PubChem CID 9941379: Bremelanotide, C50H68N14O10, 1025.2 g/mol. · pubchem:9941379

CAS registry number 189691-06-3. · pubchem:9941379

IUPAC name: (3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid. · pubchem:9941379

Where the evidence actually sits

Established100%

Proportion of the 2 claims about Bremelanotide standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Bremelanotide: First Approval. (2019) · establishedBremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. (2019) · established20192019

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Bremelanotide yet.

Dose evidence, rung by rung

A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier
    • Bremelanotide: First Approval. · pmid 31429064 · 2019
    • Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. · pmid 31599840 · 2019
  3. Observational evidence · resolved human data at the emerging tier: thin, or contested

    nothing resolved on this rung

  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.